New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:35 EDTLPTNLpath's Lpathomab for traumatic brain injury receives $1.7M development grant
Lpath received official notification from the National Institutes of Neurological Diseases and Stroke that it has been awarded a $1.7M, 2.5-year grant to develop its antibody therapeutic, Lpathomab against the bioactive lipid lysophosphatidic acid for the treatment of traumatic brain injury. The Phase l amount of $224K will fund studies designed to repeat in rats the efficacy previously demonstrated in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5M will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.
News For LPTN From The Last 14 Days
Check below for free stories on LPTN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LPTN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use